The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Avlayah tividenofusp alfa-eknm New biologicPriority review | Denali Therapeutics Inc. | 🇺🇸 US 2026-03-24 | Order → | |
| Rezurock belumosudil OrphanConditionalAdditional monitoring | Sanofi Winthrop Industrie | Graft vs Host Disease | 🇪🇺 EU 2026-03-24 | Order → |
| Atoncy atomoxetine hydrochloride New dosage form | Map77 | 🇺🇸 US 2026-03-20 | Order → | |
| Flavalta epinephrine bitartrate, lidocaine hydrochloride New formulation or manufacturer | Deproco | 🇺🇸 US 2026-03-19 | Order → | |
| Icotyde icotrokinra hydrochloride New molecular entityPriority review | Janssen Biotech | 🇺🇸 US 2026-03-17 | Order → | |
| Lynavoy linerixibat New molecular entity | Intercept | 🇺🇸 US 2026-03-17 | Order → | |
| Pylarify Truvu piflufolastat f-18 New formulation or manufacturer | Aphelion | 🇺🇸 US 2026-03-06 | Order → | |
| Duloxetine Hydrochloride duloxetine hydrochloride New formulation or manufacturer | Almatica | 🇺🇸 US 2026-02-27 | Order → | |
| Prezcobix cobicistat, darunavir and cobicistat, darunavir ethanolate New dosage form | Janssen Prods | 🇺🇸 US 2026-02-27 | Order → | |
| Yuviwel navepegritide New molecular entityPriority review | Ascendis | 🇺🇸 US 2026-02-27 | Order → | |
| Desmoda desmopressin acetate New dosage form | Eton | 🇺🇸 US 2026-02-25 | Order → | |
| Loargys pegzilarginase-nbln New biologicPriority review | Immedica Pharma Ab | 🇺🇸 US 2026-02-23 | Order → | |
| Bysanti milsaperidone New molecular entity | Vanda Pharms Inc | 🇺🇸 US 2026-02-20 | Order → | |
| Favlyxa fluorouracil New formulation or manufacturer | Avyxa Holdings | 🇺🇸 US 2026-02-20 | Order → | |
| Medical Air, Usp | Industrial Welding Supply Co Of Harvey Inc | 🇺🇸 US 2026-02-17 | Order → | |
| Anktiva nogapendekin alfa inbakicept ConditionalAdditional monitoring | Immunitybio Ireland Limited | Non-Muscle Invasive Bladder Neoplasms | 🇪🇺 EU 2026-02-16 | Order → |
| Avopef etoposide New dosage form | Avyxa Holdings | 🇺🇸 US 2026-02-13 | Order → | |
| Rybrevant Faspro amivantamab and hyaluronidase-lpuj New biologic | Janssen Biotech | 🇺🇸 US 2026-02-13 | Order → | |
| Adquey difamilast New molecular entity | Acrotech Biopharma | 🇺🇸 US 2026-02-12 | Order → | |
| Aumseqa Aumolertinib Additional monitoring | SFL Pharmaceuticals Deutschland GmbH | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2026-02-12 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.